Vixarelimab in Patients With Prurigo Nodularis
JAMA Dermatology · 2026
DOI: 10.1001/jamadermatol.2025.4950 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JAMA Dermatology, 2026. Verfasst von Sonja Ständer und 6 weiteren Autor:innen. Beteiligte Einrichtung: Section for Pruritus Medicine, Department of Dermatology, Münster University Hospital, Münster, Germany. Hauptthemen laut MEDLINE: Prurigo, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Prurigo nodularis (PN) is a chronic inflammatory skin disease characterized by severe pruritus and nodule formation, significantly affecting patients’ quality of life. There is an unmet need for effective therapies to address both symptoms and disease progression.
Objective
To evaluate the efficacy, safety, tolerability, and pharmacokinetics of monthly dosed vixarelimab in participants with moderate to severe PN. Design, Setting, and Participants This double-blind (DB), placebo-controlled, phase 2b randomized clinical trial was conducted from December 1, 2020, to August 24, 2023, across 72 centers in the US, Canada, Europe, and Asia. The study included male and female participants aged 18 to 80 years with physician-diagnosed PN of at least 6 months’ duration and moderate to severe pruritus. Data were analyzed from October 2023 to March 2024.
Interventions
Participants were randomized into 4 arms during the 16-week DB period: vixarelimab, 540 mg (high-dose group); vixarelimab, 360 mg (mid-dose group); vixarelimab, 120 mg (low-dose group); or placebo. Vixarelimab and placebo were administered subcutaneously every 4 weeks. During the 36-week open-label extension, all participants received vixarelimab, 360 mg, every 2 weeks. Main Outcomes and Measures Key outcomes included percentage change from baseline in the Worst Itch Numeric Rating Scale (WI-NRS) at week 16, the proportion of participants achieving at least a 4-point reduction in WI-NRS at week 16, and the proportion achieving scores of 0 or 1 in the PN Investigator Global Assessment at week 16.
Results
Of 190 randomized participants, 189 received 1 or more doses of the study drug (141 vixarelimab, 48 placebo). A total of 114 (60.3%) were female, 75 (39.7%) were male, and the mean (SD) age was 55.4 (13.8) years. There were 47 participants in the high-dose vixarelimab group, 47 in the mid-dose group, 47 in the low-dose group, and 48 in the placebo group. Vixarelimab significantly reduced mean (SE) WI-NRS scores at week 16 compared with placebo across all doses (vixarelimab at high-dose, mid-dose, and low-dose levels: −56.2% [4.84], −51.0% [4.83], and −33.0% [4.86], respectively; placebo, −14.5% [4.76]). Clinically meaningful 4-point or greater reductions in WI-NRS were achieved by 31 (66.0%), 29 (61.7%), and 14 (29.8%) in the high-dose, mid-dose, and low-dose vixarelimab groups, respectively, compared with 8 (16.7%) in the placebo group. PN Investigator Global Assessment scores of 0 or 1 were also higher in vixarelimab groups (high-dose group, 18 [38.3%]; mid-dose group, 14 [29.8%]; low-dose group, 7 [14.9%]; placebo group, 5 [10.4%]). No fatal or serious drug-related treatment-emergent adverse events were reported during the study, and no serious treatment-related treatment-emergent adverse events were observed during the DB period. Conclusions and Relevance In this phase 2b randomized clinical trial, vixarelimab demonstrated rapid, sustained, dose-dependent clinical benefits in patients with PN, with a favorable safety profile. Trial Registration ClinicalTrials.gov Identifier: NCT03816891
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Section for Pruritus Medicine, Department of Dermatology, Münster University Hospital, Münster, Germany.
- University of Miami Miller School of Medicine, Miami, Florida.
- UCLA School of Medicine, Los Angeles, California.
- Genentech Inc, South San Francisco, California.
- Kiniksa Pharmaceuticals, Lexington, Massachusetts.
Zitieren
APA
Ständer, S., Yosipovitch, G., Sofen, H., Abramzon, D., Galanter, J., Wang, S., & Paolini, J. F. (2026). Vixarelimab in Patients With Prurigo Nodularis. JAMA Dermatology. https://doi.org/10.1001/jamadermatol.2025.4950
Vancouver
Ständer S, Yosipovitch G, Sofen H, Abramzon D, Galanter J, Wang S, et al. Vixarelimab in Patients With Prurigo Nodularis. JAMA Dermatology. 2026. doi:10.1001/jamadermatol.2025.4950
BibTeX
@article{Stnder2026,
author = {Ständer, Sonja and Yosipovitch, Gil and Sofen, Howard and Abramzon, Daniel and Galanter, Joshua and Wang, Sheldon and Paolini, John F},
title = {Vixarelimab in Patients With Prurigo Nodularis},
journal = {JAMA Dermatology},
year = {2026},
doi = {10.1001/jamadermatol.2025.4950}
}
EUVIMED